Navigation Links
China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
Date:11/25/2009

HARBIN, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company recently passed the Chinese National Institute for the Control of Pharmaceutical and Biological Products ("ICPBP") examination for two of its new products: its Diagnostic Kit for Human Prostate Specific Antigen (Colloidal Gold) and its Determination Kit for Luteinizing Hormone (Colloidal Gold).

The clinical trials for both products have been completed earlier. As the examination by ICPBP is usually the last material procedure toward the final production approval for biological testing products, the Company expects to receive the final approval from the State Food and Drug Administration (SFDA) in China for the production of both products by the end of 2009. Formal production for the two new products is expected to begin in 2010.

The Diagnostic Kit for Human Prostate Specific Antigen (Colloidal Gold) can be used in early diagnosis of human prostate disorders, hyperplasia and cancer, because the concentration of Prostate Specific Antigen ("PSA") is an important parameter in clinical treatment of prostate related diseases.

The Determination Kit for Luteinizing Hormone (Colloidal Gold) is used in the diagnosis of female sterility. According to research by World Health Organization, 5%-8% of married couples in developed countries are suffering from the sterility. In China, sterility patients account for nearly 10% of the total population at the age of procreation. This number keeps increasing in China due to various reasons including diseases, conception control and social stress.

"We are excited to have made such great progress in the development of these new products and look forward to receiving SFDA approval for the production of both of them very soon," commented Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "We are fully committed to increasing our drug portfolio by bringing quality new products into domestic as well as international market."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
    China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-5399-4069
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:     +1-646-213-1915
     Email:   crocker.coulson@ccgir.com
     Website: www.ccgirasia.com

SOURCE China Sky One Medical, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
2. China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results
3. China Medicine Announces Strong Third Quarter 2009 Results
4. Chindex International Announces Participation in Brean Murray, Carret & Co. 2009 China Growth Conference
5. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
6. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
8. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
9. China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
10. Varian Medical Systems to Exhibit a Wide Selection of Flat Panel X-Ray Image Detectors and X-Ray Tubes at the CMEF Show in Chengdu, China
11. China Medical Technologies to Hold its Annual General Meeting on November 16, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
(Date:5/24/2016)... , May 24, 2016 ... den Markt gebracht, die es Ärzten erlaubt, ihre ... zu behandeln: MDLinking kombiniert Live Streaming mit einer ... Umfeld zu kommunizieren. Mediziner in Europa, Afrika, Asien ... sich bereits für die Plattform registriert. ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... More than ... so it is not surprising that bariatric surgery has received increased attention in recent ... explains. Of course, when it comes to weight loss, most people are familiar with ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... An influential ... for a third time to shed lights on the variety of topics detailing why ... stories, “Nurse Appreciation” tackles why this career has gone from being in a major ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to ... who are unaware of the plight of aphasia. In collaboration with the American ... Awareness” campaign. , The link between stroke and aphasia is relatively unknown, but ...
Breaking Medicine News(10 mins):